A new model for analyzing immunomodulation of T cell responses induced by oral administration of islet cell antigens.
Based on the coimmunization of BALB/c mice with insulin and ovalbumin, we here describe a feasible efficacy model for analyzing the tolerogenic effect of the oral administration of sequestered antigens-for example, islet-specific proteins such as insulin and GAD65.
Bregenholt
Søren
S
Islet Discovery Research and Clinical Drug Development, Novo Nordisk, Novo Alle, Bagsvaerd, Denmark. sqbr@novonordisk.com
Wang
Mikala
M
Zdravkovic
Maja
M
Dyrberg
Thomas
T
Petersen
Jacob S
JS
D000284:Administration, Oral; D000818:Animals; D001324:Autoantigens / Q000008:administration & dosage* / Q000276:immunology / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D007108:Immune Tolerance / Q000187:drug effects*; D007328:Insulin / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology; D007515:Islets of Langerhans / Q000276:immunology*; D008198:Lymph Nodes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*
D001324:Autoantigens; D007328:Insulin